The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
The FDA has proposed excluding the active ingredients in popular GLP-1 obesity and diabetes medications from the list of substances eligible for compounding. This move could cut off access to lower-cost compounded versions for millions of patients. Here is what you need to know and what steps to consider now.
The FDA has approved Teva Pharmaceuticals' generic version of semaglutide injection, the active ingredient in Wegovy, for chronic weight management. Expected to cost up to 60% less than brand-name Wegovy, this approval could dramatically expand access for millions of people. Here's what patients need to know right now.
Australia's Pharmaceutical Benefits Scheme will not list Mounjaro (tirzepatide) after a breakdown in pricing negotiations with manufacturer Eli Lilly. For Australians living with obesity or type 2 diabetes, this decision has real consequences. Here's what's happening and what your options may look like.
A newly discovered enzyme could hold the key to making GLP-1 medications like Ozempic more effective. Researchers believe targeting this enzyme may extend how long GLP-1 stays active in your body — potentially improving weight loss and blood sugar outcomes.
A man who purchased what he believed to be a GLP-1 medication through an unverified online source is now facing devastating neurological consequences. His story is a stark reminder that not all GLP-1 products are what they claim to be. Here's what you need to know to protect yourself.
Losing weight on a GLP-1 medication feels like a win — until you realize some of that weight might be muscle. New research comparing semaglutide and tirzepatide raises important questions about body composition that every GLP-1 user should understand.
Most people starting a GLP-1 medication know about nausea and fatigue. But emerging research is surfacing side effects that rarely make the headline list. Understanding them early can help you and your doctor make smarter, safer decisions.
Weight loss gets all the headlines, but researchers are increasingly focused on something else GLP-1 medications appear to do: quiet chronic inflammation throughout the body. This mechanism may explain why these drugs seem to protect the heart, brain, kidneys, and joints in ways that go far beyond the number on the scale. Here's what you need to know.
.avif)